Jyong Biotech Ltd. Ordinary Shares - Asset Resilience Ratio
Jyong Biotech Ltd. Ordinary Shares (MENS) has an Asset Resilience Ratio of 44.80% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MENS current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Jyong Biotech Ltd. Ordinary Shares's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MENS total assets.
Liquid Assets Composition Over Time
This chart breaks down Jyong Biotech Ltd. Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Jyong Biotech Ltd. Ordinary Shares for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.88 Million | 44.8% |
| Total Liquid Assets | $16.88 Million | 44.80% |
Asset Resilience Insights
- Very High Liquidity: Jyong Biotech Ltd. Ordinary Shares maintains exceptional liquid asset reserves at 44.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jyong Biotech Ltd. Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Jyong Biotech Ltd. Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266 |
Biotechnology | 0.54% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Galecto Inc
NASDAQ:GLTO |
Biotechnology | 0.00% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 0.69% |
|
Ovid Therapeutics Inc
NASDAQ:OVID |
Biotechnology | 45.65% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
Annual Asset Resilience Ratio for Jyong Biotech Ltd. Ordinary Shares (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Jyong Biotech Ltd. Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $8.25 Million | -- |
| 2022-12-31 | 1.07% | $94.00K | $8.74 Million | -18.37pp |
| 2021-12-31 | 19.44% | $1.83 Million | $9.43 Million | +14.27pp |
| 2020-12-31 | 5.17% | $664.00K | $12.84 Million | -- |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for t… Read more